LeWitt P A
Wayne State University, School of Medicine, Detroit, Mich.
Eur Neurol. 1993;33 Suppl 1:24-30. doi: 10.1159/000118534.
The advance of Parkinson's disease has been suspected to be an outcome of oxidative stresses related to the metabolism of dopamine. Several recent studies have tested whether deprenyl (selegiline) or alpha-tocopherol (vitamin E) might attenuate the progression of Parkinson's disease. Although preliminary results of an 800-patient controlled clinical trial (DATATOP) suggested in 1989 that neuroprotection might be achieved with deprenyl, more recent analysis has questioned this conclusion. The apparent protective effect of deprenyl is lost after 1 year of treatment, and the drug's symptomatic antiparkinsonian effects confound an understanding of actions on the underlying disease. In the DATATOP trial, no neuroprotection was achieved with alpha-tocopherol. Methods developed in the deprenyl trials and newly discovered CSF markers of Parkinson's disease may be useful tools for future investigations of neuroprotective strategies against Parkinson's disease.
帕金森病的进展被怀疑是与多巴胺代谢相关的氧化应激的结果。最近的几项研究测试了司来吉兰（丙炔苯丙胺）或α-生育酚（维生素E）是否可能减缓帕金森病的进展。尽管1989年一项纳入800名患者的对照临床试验（DATATOP）的初步结果表明，丙炔苯丙胺可能实现神经保护，但最近的分析对此结论提出了质疑。丙炔苯丙胺的明显保护作用在治疗1年后消失，而且该药物的抗帕金森病症状作用混淆了对其对潜在疾病作用的理解。在DATATOP试验中，α-生育酚未实现神经保护。丙炔苯丙胺试验中开发的方法以及新发现的帕金森病脑脊液标志物可能是未来抗帕金森病神经保护策略研究的有用工具。
